Clinical trials: Hematopoietic Cell Transplantation
Stem Cell Transplant Complications, Graft Vs Host Disease
Multidisciplinary Intervention In Chronic GVHD
This research is being done to evaluate the feasibility and efficacy of a multidisciplinary, patient-centered intervention, Horizons Program, versus minimally enhanced standard care to improve quality of life, symptom burden and…
- Conditions
- Stem Cell Transplant Complications, Graft Vs Host Disease, Coping Skills, Quality of Life
- Trial name
- NCT04479995
- Testing
- Horizon Program, Usual Care
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
RATIONALE: Lenalidomide may stop the growth of cancer by blocking blood flow to the tumor. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT01045928
- Testing
- lenalidomide, rituximab, polymerase chain reaction
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Plasma Cell Myeloma, Plasmacytosis
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase I/II trial studies the safety and best dose of melphalan and bortezomib when given prior to an autologous stem cell transplant and to see how well they work in treating patients with multiple myeloma.
- Conditions
- Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT02353572
- Testing
- Melphalan, Bortezomib, Dexamethasone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Acute Gastrointestinal Graft vs Host Disease
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
Use of an oral topically-active glucocorticoid with limited side effects will control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
- Trial name
- SUPPORTS (NCT00926575)
- Testing
- oral beclomethasone 17,21-dipropionate
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Soligenix
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor, Minimal Residual Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03624530
- Testing
- Tyrosine kinase inhibitor (TKIs)
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematologic Diseases, Stem Cell Transplantation
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
This study is designed to assess the hypothesis that the lipopolysaccharide (LPS) activity index can be quantified early after transplantation, as well as the the PhosphoLipid Transfer Protein (PLTP) activity and these both…
- Trial name
- MetAlloLip (NCT03918343)
- Testing
- Blood sample
- Where
- 2 sites in France
- Volunteers
- 95 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Breast Cancer, Chronic Myeloproliferative Disorders
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host disease.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00651716
- Testing
- flow cytometry, laboratory biomarker analysis, Data Collection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Blood Diseases
Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment
The endogenous growth factor granulocyte (G-CSF) stimulates the proliferation and differentiation of hematopoietic progenitors commissioned to mature as neutrophils and activated granulocytes mature neutrophils.
- Trial name
- NCT02806791
- Testing
- FILGRASTIM
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07256210
- Testing
- Donor-derived Natural Killer Cell
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
HCT With PTCy in Higher-risk MDS
This study is conducted to evaluate the efficacy of post-transplantation cyclophosphamide with myeloablative or reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with…
- Trial name
- NCT06098313
- Testing
- Cyclophosphamide
- Where
- South Korea
- Volunteers
- 113 people
- Sponsor
- Asan Medical Center
Myelodysplastic Syndrome
Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)
This is a multicenter, multinational, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to…
- Trial name
- NCT01062490
- Testing
- Treosulfan
- Where
- Finland
- Volunteers
- 45 people
- Sponsor
- medac GmbH
Acute Lymphoblastic Leukemia
Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
The survival of adult patients with standard-risk acute lymphoblastic leukemia(ALL) need to improve. We want to compare the efficacy of haplo-identical hematopoietic stem cell transplantation (HSCT) with chemotherapy for…
- Trial name
- NCT02042690
- Testing
- Haplo-identical HSCT, Chemotherapy
- Where
- 5 sites in China
- Volunteers
- 131 people
- Sponsor
- Peking University
Lymphoma, Multiple Myeloma
Telomerase Activity as a Marker For Mobilization Quality
Autologous hematopoietic cell transplantation (HCT) is a treatment strategy used as advanced line therapy for different malignancies, mainly hematological.
- Trial name
- NCT01555359
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Rabin Medical Center
Refractory Acute Myeloid Leukemia, Early Relapses of Acute Myeloid Leukemia
IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML
The primary objective is to evaluate the efficacy and toxicity of high versus low intensity therapy options in patients with refractory forms and early relapses of acute myeloid leukemia (R/R AML) who are scheduled for allogeneic…
- Trial name
- NCT06418776
- Testing
- Intensive therapy, Low intensity therapy
- Where
- Russia
- Volunteers
- 198 people
- Sponsor
- National Research Center for Hematology, Russia
Allogeneic Stem Cell Transplantation in Elderly Patients
Allogeneic Stem Cell Transplantation (ALLO-SCT) in Elderly: 17-years Retrospective GITMO Survey
The age of patients' population is increasing every year, as the life expectancy. Thus, the incidence and prevalence of hematological cancers is increasing.
- Trial name
- NCT04469985
- Where
- Italy
- Volunteers
- 2,061 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Multiple Myeloma in Relapse, Multiple Myeloma Progression
Tinostamustine Conditioning and Autologous Stem Cell
Phase 1 The primary objectives of Phase 1 of this study are to: Establish the safety, toxicity, and maximum tolerated dose (MTD) of the tinostamustine conditioning regimen.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma With Failed Remission
- Trial name
- TITANIUM1 (NCT03687125)
- Testing
- Tinostamustine, Autologous Stem Cell Transplant (ASCT)
- Where
- 12 sites in United States, Norway and 1 more
- Volunteers
- 6 people
- Sponsor
- Mundipharma-EDO GmbH
T Lymphoblastic Lymphoma
Allo-HSCT vs ASCT in Adult T-LBL
Autologous hematopoietic stem cell transplantation (ASCT) is the important consolidation for adult T-LBL. Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is also the important consolidation for adult T-LBL.
- Trial name
- TROPHY-NHL01 (NCT06741813)
- Testing
- ASCT, Allo-HSCT
- Volunteers
- 230 people
- Sponsor
- Peking University People's Hospital
GVHD
Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis
Post-transplantation cyclophosphamide (PTCY) is considered as major graft versus host disease (GVHD) prophylaxis. In our previous study, the investigators demonstrated that the standard dose PTCY of 50mg/kg with tacrolimus and…
- Trial name
- NCT06000982
- Testing
- PTCY
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hematologic Diseases, Bone Marrow Transplantation
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Bone marrow transplantation is both a great treatment for patients with hematological diseases. It is also one of the only hopes of staying alive by "starting from scratch". It is a trying life experience, at all its stages.
- Conditions
- Hematologic Diseases, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation
- Trial name
- NSFM (NCT06148610)
- Testing
- NewSpringForMe digital solution
- Where
- France
- Volunteers
- 170 people
- Sponsor
- Fonds de Dotation HTC Project
Myelofibrosis
JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis
JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with primary or secondary myelofibrosis : a prospective phase II
- Trial name
- NCT01795677
- Testing
- Ruxolotinib
- Where
- France
- Volunteers
- 78 people
- Sponsor
- French Innovative Leukemia Organisation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.